Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3060)
All Articles published online
|
May 14, 2009 (publication date) through Nov 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zold E, Nagy A, Devenyi K, Zeher M, Barta Z. Successful use of adalimumab for treating fistulizing Crohn’s disease with pyoderma gangrenosum: Two birds with one stone. World J Gastroenterol 2009; 15(18): 2293-2295 [PMID: 19437575 DOI: 10.3748/wjg.15.2293] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i18/2293.htm |
| Number | Citing Articles |
| 1 |
Goher Rahbour, Janindra Warusavitarne, Ailsa L. Hart, Philip J. Tozer, Mohammad R. Ullah, Gregory P. Thomas, Simon M. Gabe, Stella C. Knight, Hafid O. Al-Hassi, Carolynne J. Vaizey. Pilot study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas. International Journal of Surgery 2017; 41: 127 doi: 10.1016/j.ijsu.2017.03.079
|
| 2 |
Uwe Wollina, Gunter Haroske. Pyoderma gangraenosum. Current Opinion in Rheumatology 2011; 23(1): 50 doi: 10.1097/BOR.0b013e328341152f
|
| 3 |
Shin-ichiro Ohmura, Yoichiro Homma, Shiho Hanai, Yoshiro Otsuki, Toshiaki Miyamoto. Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: A case report and review of the literature. Modern Rheumatology Case Reports 2023; 7(1): 9 doi: 10.1093/mrcr/rxac023
|
| 4 |
Philip J. Hampton, Stephanie Ball. Rook's Textbook of Dermatology. 2024; : 1 doi: 10.1002/9781119709268.rook049
|
| 5 |
Afsaneh Alavi, Lars E. French, Mark D. Davis, Alain Brassard, Robert S. Kirsner. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. American Journal of Clinical Dermatology 2017; 18(3): 355 doi: 10.1007/s40257-017-0251-7
|
| 6 |
Stephan R. Vavricka, Alain Schoepfer, Michael Scharl, Peter L. Lakatos, Alexander Navarini, Gerhard Rogler. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2015; 21(8): 1982 doi: 10.1097/MIB.0000000000000392
|
| 7 |
Hakim Ben Abdallah, Karsten Fogh, Rikke Bech. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review. International Wound Journal 2019; 16(2): 511 doi: 10.1111/iwj.13067
|
| 8 |
A. Agarwal, J. M. Andrews. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Alimentary Pharmacology & Therapeutics 2013; 38(6): 563 doi: 10.1111/apt.12431
|
| 9 |
Emanual Maverakis, Angelo V. Marzano, Stephanie T. Le, Jeffrey P. Callen, Marie-Charlotte Brüggen, Emmanuella Guenova, Joachim Dissemond, Kanade Shinkai, Sinéad M. Langan. Pyoderma gangrenosum. Nature Reviews Disease Primers 2020; 6(1) doi: 10.1038/s41572-020-0213-x
|
| 10 |
Clóvis Luíz Konopka, Geórgia Andrade Padulla, Michele Purper Ortiz, Anderson Kahl Beck, Mariana Rechia Bitencourt, Diogo Chagas Dalcin. Pioderma Gangrenoso: um Artigo de Revisão. Jornal Vascular Brasileiro 2013; 12(1): 25 doi: 10.1590/S1677-54492013000100006
|
| 11 |
Kenshi Yamasaki, Keiichi Yamanaka, Yiwei Zhao, Shunsuke Iwano, Keiko Takei, Koji Suzuki, Toshiyuki Yamamoto. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study. The Journal of Dermatology 2020; 47(12): 1383 doi: 10.1111/1346-8138.15533
|
| 12 |
Simone Garcovich, Clara De Simone, Emilio Berti, Angelo Valerio Marzano. Drug management of neutrophilic dermatoses. Expert Review of Clinical Pharmacology 2017; 10(10): 1119 doi: 10.1080/17512433.2017.1356719
|
| 13 |
Maddalena Zippi, Roberta Pica, Daniela De Nitto, Paolo Paoluzi. Biological therapy for dermatological manifestations of inflammatory bowel disease. World Journal of Clinical Cases 2013; 1(2): 74-78 doi: 10.12998/wjcc.v1.i2.74
|
| 14 |
Charlotte Hurabielle, Pierre Schneider, Clotilde Baudry, Martine Bagot, Matthieu Allez, Manuelle Viguier. Certolizumab pegol – A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn’s disease. Journal of Dermatological Treatment 2016; 27(1): 67 doi: 10.3109/09546634.2015.1034075
|
| 15 |
G. Andrisani, L. Guidi, A. Papa, A.E. Potenza, D. Cervelli, A. Armuzzi. A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgery. Journal of Crohn's and Colitis 2013; 7(5): 421 doi: 10.1016/j.crohns.2012.07.021
|
| 16 |
Bruno Rafael Ramos de Mattos, Maellin Pereira Gracindo Garcia, Julia Bier Nogueira, Lisiery Negrini Paiatto, Cassia Galdino Albuquerque, Caique Lopes Souza, Luís Gustavo Romani Fernandes, Wirla Maria da Silva Cunha Tamashiro, Patricia Ucelli Simioni, Even Fossum. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators of Inflammation 2015; 2015(1) doi: 10.1155/2015/493012
|
| 17 |
P. Al Ghazal, J. Dissemond. Multilokuläres Pyoderma gangraenosum nach Uterusresektion. Der Chirurg 2012; 83(3): 254 doi: 10.1007/s00104-011-2259-5
|
| 18 |
I. Sick, T. Ruzicka. Pyoderma gangraenosum. Journal für Ästhetische Chirurgie 2011; 4(1): 7 doi: 10.1007/s12631-010-0105-0
|
| 19 |
Ignasi Figueras Nart, Sara Martín-Sala, Alba Álvarez-Abella, Anna Jucglà Serra. Pioderma gangrenoso. Piel 2012; 27(3): 132 doi: 10.1016/j.piel.2011.10.012
|
| 20 |
A.V. Nikitin, G.V. Volynets, T.A. Skvortsova, M.S. Kapranova. Extraintestinal manifestations of inflammatory bowel disease. Dokazatel'naya gastroenterologiya 2023; 12(1): 93 doi: 10.17116/dokgastro20231201193
|
| 21 |
F. Argüelles-Arias, L. Castro-Laria, T. Lobatón, M. Aguas-Peris, M. Rojas-Feria, M. Barreiro-de Acosta, P. Soto-Escribano, M. Calvo-Moya, D. Ginard-Vicens, M. Chaparro-Sánchez, M. Hernández-Durán, B. Castro-Senosiain, A. Fernández-Villaverde, V. García-Sánchez, E. Domínguez-Muñoz, A. Caunedo-Álvarez, J. M. Herrerías-Gutiérrez. Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease. Digestive Diseases and Sciences 2013; 58(10): 2949 doi: 10.1007/s10620-013-2762-2
|
| 22 |
Raj Patel, John M Cafardi, Nital Patel, Naveed Sami, Jennifer A Cafardi. Tumor necrosis factor biologics beyond psoriasis in dermatology. Expert Opinion on Biological Therapy 2011; 11(10): 1341 doi: 10.1517/14712598.2011.590798
|
| 23 |
Kenta Iwahashi, Yuichiro Kuroki, Yuichi Takano, Masatsugu Nagahama. Effective use of switching biologics for ulcerative colitis complicated with pyoderma gangrenosum and primary sclerosing cholangitis. BMJ Case Reports 2021; 14(5): e241744 doi: 10.1136/bcr-2021-241744
|
| 24 |
Fatima McKenzie, Megan Arthur, Alex G. Ortega-Loayza. Pyoderma Gangrenosum: What Do We Know Now?. Current Dermatology Reports 2018; 7(3): 147 doi: 10.1007/s13671-018-0224-y
|
| 25 |
Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings, Alex G. Ortega-Loayza. Biologic and small-molecule medications in the management of pyoderma gangrenosum. Journal of Dermatological Treatment 2019; 30(3): 264 doi: 10.1080/09546634.2018.1506083
|
| 26 |
Ahmed Hadi, Mark Lebwohl. Clinical features of pyoderma gangrenosum and current diagnostic trends. Journal of the American Academy of Dermatology 2011; 64(5): 950 doi: 10.1016/j.jaad.2010.01.049
|
| 27 |
Kenshi Yamasaki, Keiichi Yamanaka, Yiwei Zhao, Shunsuke Iwano, Keiko Takei, Koji Suzuki, Toshiyuki Yamamoto. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52‐week phase 3 open‐label study. The Journal of Dermatology 2022; 49(5): 479 doi: 10.1111/1346-8138.16337
|
| 28 |
Robert Löfberg, Edouard V. Louis, Walter Reinisch, Anne M. Robinson, Martina Kron, Anne Camez, Paul F. Pollack. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE. Inflammatory Bowel Diseases 2012; 18(1): 1 doi: 10.1002/ibd.21663
|
| 29 |
János Fehér, Gabriella Lengyel. The effectivity and safety of the biological therapy with adalimumab. Orvosi Hetilap 2009; 150(26): 1215 doi: 10.1556/oh.2009.28681
|
| 30 |
|
| 31 |
Shintaro Sagami, Yoshitaka Ueno, Shinji Tanaka, Kenta Nagai, Ryohei Hayashi, Kazuaki Chayama. Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering Conditions. Internal Medicine 2015; 54(17): 2167 doi: 10.2169/internalmedicine.54.4853
|
| 32 |
Anthony D. Ormerod, Philip J. Hampton. Rook's Textbook of Dermatology, Ninth Edition. 2016; : 1 doi: 10.1002/9781118441213.rtd0050
|
| 33 |
José Mª Mir Bonafé, Emilia Fernández López, Gonzalo Nieto González, Pablo De Unamuno Pérez. Manifestaciones cutáneas en enfermedad inflamatoria intestinal. Piel 2011; 26(9): 451 doi: 10.1016/j.piel.2011.03.017
|
| 34 |
E.M. DeFilippis, S.R. Feldman, W.W. Huang. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. British Journal of Dermatology 2015; 172(6): 1487 doi: 10.1111/bjd.13493
|
| 35 |
Irune Cariñanos, Manuel Barreiro-De Acosta, Eugeni Domènech. Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. Inflammatory Bowel Diseases 2011; 17(12): E153 doi: 10.1002/ibd.21723
|
| 36 |
I. Sick, B. Trautner, T. Ruzicka. Chirurgische Therapie beim Pyoderma gangraenosum. Der Hautarzt 2012; 63(7): 577 doi: 10.1007/s00105-011-2269-8
|
| 37 |
Vishal Ghevariya, Shashideep Singhal, Sury Anand. The skin: a mirror to the gut. International Journal of Colorectal Disease 2013; 28(7): 889 doi: 10.1007/s00384-012-1637-x
|